Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel.

Chronic hepatitis C (HCV) infection is currently oneof the most clinically relevant comorbidities in theHIV population; overall, it affects one third of HIV-positive individuals [1]. Progression to end-stage liverdisease occurs faster in coinfected patients [2–4] anddecompensated cirrhosis is one of the main causes ofhospitalization and death in this population [5–8].However, the risk of hepatotoxicity using antiretroviraldrugs is increased in subjects with underlying HCVinfection [9,10]. Therefore, the optimal managementof chronic HCV in HIV-positive patients is currentlyapriority.Several guidelines for caring for HCV infection in HIV-positive individuals have been released [11–15]. Becausenew and relevant information has recently appeared, it isconvenient to update them. Eleven areas have beenidentified in which new recommendations are particu-larly needed:management of patients with persistently normalaminotransferasesliver fibrosis assessment: when and howpredictors of response to anti-HCV therapy in coinfectedpatientsoptimal dosages of pegylated interferon (pegIFN) andribavirin (RBV)optimal duration of anti-HCV therapytreatment of non-responders and/or relapserscare of patients with end-stage liver diseasetreatment of acute HCV infection in HIV-infectedindividualsmanagement of patients with multiple hepatitis virusesinteractions between HCV medications and antiretroviraldrugshepatotoxicity of antiretroviral drugs.

[1]  V. Soriano,et al.  Liver fibrosis stage and HCV genotype distribution in HIV-HCV coinfected patients with persistently normal transaminases. , 2007, AIDS research and human retroviruses.

[2]  V. Soriano,et al.  Clearance of hepatitis C virus in HIV‐infected patients with multiple chronic viral hepatitis , 2007, Journal of viral hepatitis.

[3]  V. Soriano,et al.  Treatment of chronic hepatitis B or C in HIV-infected patients with dual viral hepatitis. , 2007, The Journal of infectious diseases.

[4]  L. Waters,et al.  8th International Congress on Drug Therapy in HIV Infection , 2007 .

[5]  R. Bonomo,et al.  46th Interscience Conference on Antimicrobial Agents and Chemotherapy. , 2007, Future microbiology.

[6]  G. Pialoux,et al.  Reactivation of hepatitis B virus replication during peginterferon-ribavirin therapy in an HIV/hepatitis C virus-co-infected patient with isolated anti-hepatitis B core antibodies. , 2007, AIDS.

[7]  J. Montaner,et al.  Histological response to pegIFNα-2a (40KD) plus ribavirin in HIV–hepatitis C virus co-infection , 2006, AIDS.

[8]  E. Rosenberg,et al.  Regression of liver fibrosis in hepatitis C virus/HIV-co-infected patients after treatment with pegylated interferon plus ribavirin. , 2006 .

[9]  C. Katlama,et al.  The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial , 2006, The Lancet.

[10]  B. Ledergerber,et al.  Impact of Lamivudine on the Risk of Liver-Related Death in 2,041 Hbsag- and HIV-Positive Individuals: Results from an Inter-Cohort Analysis , 2006, Antiviral therapy.

[11]  R. Andrade,et al.  Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. , 2006, Gastroenterology.

[12]  H. Jessen,et al.  Pegylated interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients. , 2006, The Journal of infection.

[13]  C. Toro,et al.  Severe Liver Disease Associated With Prolonged Exposure to Antiretroviral Drugs , 2006, Journal of acquired immune deficiency syndromes.

[14]  J. Montaner,et al.  Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection , 2006, Hepatology.

[15]  C. Katlama,et al.  Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients , 2006, AIDS.

[16]  S. Roberts,et al.  Sustained virological response rates and durability of the response to interferon‐based therapies in hepatitis C patients treated in the clinical setting , 2006, Journal of viral hepatitis.

[17]  A. Folgori,et al.  Hepatitis C virus carriers with persistently normal ALT levels: biological peculiarities and update of the natural history of liver disease at 10 years , 2006, Journal of viral hepatitis.

[18]  J. Torre-Cisneros,et al.  Low incidence of severe liver toxicity in patients receiving antiretroviral combinations including atazanavir. , 2006, The Journal of antimicrobial chemotherapy.

[19]  A. Alberti,et al.  Fibrosis progression in initially mild chronic hepatitis C , 2006, Journal of viral hepatitis.

[20]  L. McCullagh,et al.  Role of individualization of hepatitis C virus (HCV) therapy duration in HIV/HCV‐coinfected individuals * , 2006, HIV medicine.

[21]  V. Soriano,et al.  Higher risk of hyperglycemia in HIV-infected patients treated with didanosine plus tenofovir. , 2006, AIDS research and human retroviruses.

[22]  J. Altés,et al.  Efficacy and Safety of Pegylated Interferon-α2b Plus Ribavirin for the Treatment of Chronic Hepatitis C in HIV-Infected Patients , 2006 .

[23]  V. Soriano,et al.  Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients. , 2006, Journal of viral hepatitis.

[24]  B. Hunyady,et al.  599 Peg-IFN plus ribavirin therapy suppresses plasma TGF-β1, hyaluronic acid and procollagen-III-peptide levels in patients with chronic hepatitis C independently of virological response , 2006 .

[25]  F. Carrat,et al.  558 Risk factors for bacterial infections in HIV/HCV-coinfected patients during interferon plus ribavirin-based therapy , 2006 .

[26]  T. Berg,et al.  Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. , 2006, Gastroenterology.

[27]  R. Fontana.  Optimizing outcomes in hepatitis C: is treatment beyond 48 weeks ever justified? , 2006, Gastroenterology.

[28]  V. Soriano,et al.  Predictors of liver fibrosis in HIV-infected patients with chronic hepatitis C virus (HCV) infection: assessment using transient elastometry and the role of HCV genotype 3. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  S. Zeuzem,et al.  734 Peginterferon alpha-2a (PEGASYS) plus ribavirin (COPEGUS) for 16 or 24 weeks in patients with HCV genotype 2 OR 3. Final results of the accelerate trial , 2006 .

[30]  C. Datz,et al.  8 24 Week treatment regimen with peginterferon alpha-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in HCV genotype 1 or 4 ‘super-responders’ , 2006 .

[31]  J. Albrecht,et al.  744 Sustained virologic response (SVR) to interferon-alpha-2b +/- ribavirin therapy at 6 months reliably predicts long-term clearance of HCV at 5-year follow-up , 2006 .

[32]  V. Bourcier,et al.  577 Liver stiffness measurement (LSM) as a tool to measure liver fibrosis in treated patients with chronic hepatitis C (CHC) , 2006 .

[33]  P. Marcellin,et al.  11 Efficacy of standard-dose and fixed-dose induction peginterferon alpha-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) among pegylated interferon alpha-2b (12kd)/ribavirin non-responders: Interim analysis of the repeat study , 2006 .

[34]  P. Couzigou,et al.  564 Evaluation of fibrosis regression using fibroscan in HCV responder patients. A prospective controlled study , 2006 .

[35]  P. Giral,et al.  738 A one year randomized, placebo-controlled, double-blind trial of rosiglitazone in non-alcoholic steatohepatitis: Results of the flirt pilot trial , 2006 .

[36]  A. Andriulli,et al.  506 Pegylated interferon alpha-2b monotherapy and in combination with ribavirin in chronic hepatitis delta , 2006 .

[37]  P. Roderick,et al.  Performance of serum marker panels for liver fibrosis in chronic hepatitis C. , 2006, Journal of hepatology.

[38]  N. Afdhal,et al.  Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. , 2006, Gastroenterology.

[39]  G. D'offizi,et al.  Liver enzyme elevation in hepatitis C virus (HCV)-HIV-coinfected patients prior to and after initiating HAART: role of HCV genotypes. , 2006, AIDS research and human retroviruses.

[40]  M. Pinzani,et al.  Non-invasive evaluation of hepatic fibrosis: don’t count your chickens before they’re hatched , 2006, Gut.

[41]  G. Sotgiu,et al.  Influence of Genotype 3 Hepatitis C Coinfection on Liver Enzyme Elevation in HIV-1-Positive Patients After Commencement of a New Highly Active Antiretroviral Regimen: Results From the EPOKA-MASTER Cohort , 2006, Journal of acquired immune deficiency syndromes.

[42]  M. Ziol,et al.  Diagnosis of Hepatic Fibrosis and Cirrhosis by Transient Elastography in HIV/Hepatitis C Virus-Coinfected Patients , 2006, Journal of acquired immune deficiency syndromes.

[43]  C. Datz,et al.  Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection. , 2006, Journal of hepatology.

[44]  J. Torre-Cisneros,et al.  Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease , 2006, AIDS.

[45]  A. Lazzarin,et al.  Liver Fibrosis in HIV-Positive Patients With Hepatitis C Virus: Role of Persistently Normal Alanine Aminotransferase Levels , 2006, Journal of acquired immune deficiency syndromes.

[46]  P. Pontisso,et al.  Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus–coinfected patients , 2006, Hepatology.

[47]  J. Kaldor,et al.  Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies , 2006, Journal of viral hepatitis.

[48]  T. Heeren,et al.  HIV Infection Does Not Affect the Performance of Noninvasive Markers of Fibrosis for the Diagnosis of Hepatitis C Virus-Related Liver Disease , 2005, Journal of acquired immune deficiency syndromes.

[49]  M. Bajaj,et al.  Disseminated cysticercosis involving orbit, brain and subcutaneous tissue. , 2005, The Journal of infection.

[50]  M. Vogel,et al.  Orthotopic liver transplantation in human immunodeficiency virus (HIV)‐positive patients: Outcome of 7 patients from the Bonn cohort , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[51]  M. Pirisi,et al.  Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases , 2005, Hepatology.

[52]  A. Perelson,et al.  Mutagenic effects of ribavirin in vivo. , 2005, Journal of hepatology.

[53]  L. Piroth.  Liver steatosis in HIV-infected patients. , 2005, AIDS reviews.

[54]  T. Nakajima,et al.  A follow-up study to determine the value of liver biopsy and need for antiviral therapy for hepatitis C virus carriers with persistently normal serum aminotransferase. , 2005, Journal of hepatology.

[55]  P. Tien.  Management and Treatment of Hepatitis C Virus Infection in HIV-Infected Adults: Recommendations from the Veterans Affairs Hepatitis C Resource Center Program and National Hepatitis C Program Office1 , 2005, The American Journal of Gastroenterology.

[56]  V. Soriano,et al.  Effect of Ribavirin on Intracellular and Plasma Pharmacokinetics of Nucleoside Reverse Transcriptase Inhibitors in Patients with Human Immunodeficiency Virus-Hepatitis C Virus Coinfection: Results of a Randomized Clinical Study , 2005, Antimicrobial Agents and Chemotherapy.

[57]  A. Mocroft,et al.  Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. , 2005, The Journal of infectious diseases.

[58]  S. Hernandez,et al.  Single (B or C), dual (BC or BD) and triple (BCD) viral hepatitis in HIV-infected patients in Madrid, Spain , 2005, AIDS.

[59]  V. Soriano,et al.  Hepatic and Renal Safety Profile of Tenofovir in HIV-Infected Patients with Hepatitis C, Including Patients on Interferon Plus Ribavirin , 2005, HIV clinical trials.

[60]  F. Carrat,et al.  Risk Factors for Symptomatic Mitochondrial Toxicity in HIV/Hepatitis C Virus-Coinfected Patients During Interferon Plus Ribavirin-Based Therapy , 2005, Journal of acquired immune deficiency syndromes.

[61]  B. Gazzard,et al.  Transmission of Hepatitis C Virus Among HIV-Positive Homosexual Men and Response to a 24-Week Course of Pegylated Interferon and Ribavirin , 2005, Journal of acquired immune deficiency syndromes.

[62]  J. Macías,et al.  Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes , 2005, Gut.

[63]  E. Bini,et al.  Epoetin alfa once weekly improves anemia in HIV/hepatitis C virus-coinfected patients treated with interferon/ribavirin: a randomized controlled trial. , 2005, Journal of acquired immune deficiency syndromes.

[64]  V. Soriano,et al.  Early Monitoring of Ribavirin Plasma Concentrations May Predict Anemia and Early Virologic Response in HIV/Hepatitis C Virus-Coinfected Patients , 2005, Journal of acquired immune deficiency syndromes.

[65]  V. de Lédinghen,et al.  Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study , 2005, Gut.

[66]  N. Afdhal,et al.  Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. , 2005, Journal of hepatology.

[67]  V. Soriano,et al.  Impact of Ribavirin Exposure on Early Virological Response to Hepatitis C Therapy in HIV-Infected Patients with Chronic Hepatitis C , 2005, Antiviral therapy.

[68]  N. Shire,et al.  Outcomes among patients with end-stage liver disease who are coinfected with HIV and hepatitis C virus. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[69]  E. Wilkins,et al.  BHIVA guidelines on HIV and chronic hepatitis: coinfection with HIV and hepatitis B virus infection (2005) , 2005, HIV medicine.

[70]  V. Soriano,et al.  Changes in nevirapine plasma concentrations over time and its relationship with liver enzyme elevations. , 2005, AIDS research and human retroviruses.

[71]  A. Andriulli,et al.  Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. , 2005, The New England journal of medicine.

[72]  B. Clotet,et al.  Results of a Study of Prolonging Treatment with Pegylated Interferon-α2A plus Ribavirin in HIV/HCV-Coinfected Patients with No Early Virological Response , 2005, Antiviral therapy.

[73]  Giorgio Palù,et al.  Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. , 2005, Journal of hepatology.

[74]  E. Timmermans,et al.  Mitochondrial Dna Depletion in HIV-Infected Patients is More Pronounced with Chronic Hepatitis C and Enhanced following Treatment with Pegylated Interferon plus Ribavirin , 2005, Antiviral therapy.

[75]  Sheng-Nan Lu,et al.  Combination therapy with interferon‐α and ribavirin in patients with dual hepatitis B and hepatitis C virus infection , 2005, Journal of gastroenterology and hepatology.

[76]  M. Lederman,et al.  Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. , 2005, The Journal of infectious diseases.

[77]  V. Soriano,et al.  Hepatitis C Viremia in HIV/HCV-Coinfected Patients: Lower Levels in Presence of Chronic Hepatitis B , 2005, HIV clinical trials.

[78]  R. Andrade,et al.  Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. , 2005, Gastroenterology.

[79]  H. Jessen,et al.  Treatment of acute hepatitis C infection in HIV‐infected patients: a retrospective analysis of eleven cases , 2005, Journal of viral hepatitis.

[80]  C. Quereda,et al.  Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[81]  A. Alberti.  Towards more individualised management of hepatitis C virus patients with initially or persistently normal alanineaminotransferase levels. , 2005, Journal of hepatology.

[82]  N. Margot,et al.  In Vitro Combination Studies of Tenofovir and Other Nucleoside Analogues with Ribavirin against HIV-1 , 2005, Antiviral therapy.

[83]  P. Duca,et al.  Open, Randomized, Multicentre Italian Trial on Peg-Ifn plus Ribavirin versus Peg-Ifn Monotherapy for Chronic Hepatitis C in HIV-Coinfected Patients on Haart , 2005, Antiviral therapy.

[84]  V. de Lédinghen,et al.  Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. , 2005, Gastroenterology.

[85]  A. Bruchfeld,et al.  High‐dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C , 2005, Hepatology.

[86]  Raymond T Chung,et al.  Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients. , 2005, Gastroenterology.

[87]  Ming‐Lung Yu,et al.  Viral Interaction and Responses in Chronic Hepatitis C and B Coinfected Patients with Interferon-Alpha plus Ribavirin Combination Therapy , 2005, Antiviral therapy.

[88]  Christos Christidis,et al.  Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C , 2005, Hepatology.

[89]  A. Perelson,et al.  Modelling how ribavirin improves interferon response rates in hepatitis C virus infection , 2004, Nature.

[90]  F. Carrat,et al.  Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. , 2004, JAMA.

[91]  K. Reddy,et al.  Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. , 2004, Gastroenterology.

[92]  J. Pawlotsky,et al.  Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. , 2004, Journal of hepatology.

[93]  R. Bruno,et al.  Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome , 2004, AIDS.

[94]  Richard D Moore,et al.  Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir , 2004, AIDS.

[95]  J. Guest,et al.  Hepatitis C virus coinfection increases mortality in HIV-infected patients in the highly active antiretroviral therapy era: data from the HIV Atlanta VA Cohort Study. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[96]  A. Andriulli,et al.  Treatment of patients with HCV infection with or without liver biopsy , 2004, Journal of viral hepatitis.

[97]  B. McGovern.  Hepatic safety and HAART. , 2004, Journal of the International Association of Physicians in AIDS Care.

[98]  A. Wohl,et al.  Survival in patients with HIV infection and viral hepatitis B or C: a cohort study , 2004, AIDS.

[99]  D. Dieterich,et al.  Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy , 2004, AIDS.

[100]  A. León,et al.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients , 2004, AIDS.

[101]  D. Wendum,et al.  Significance of hepatitis C virus coinfection with persistently normal alanine aminotransferase levels in HIV‐1‐infected patients , 2004, HIV medicine.

[102]  V. Soriano,et al.  Long-Term Follow-Up of HIV-Infected Patients with Chronic Hepatitis C Virus Infection Treated with Interferon-Based Therapies , 2004, Antiviral therapy.

[103]  Felipe García,et al.  Depressive Symptoms after Initiation of Interferon Therapy in Human Immunodeficiency Virus-Infected Patients with Chronic Hepatitis C , 2004, Antiviral therapy.

[104]  P. Volberding,et al.  Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. , 2004, The New England journal of medicine.

[105]  J. Montaner,et al.  Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. , 2004, The New England journal of medicine.

[106]  V. Soriano,et al.  Hepatitis C virus (HCV) relapses after anti-HCV therapy are more frequent in HIV-infected patients. , 2004, AIDS research and human retroviruses.

[107]  R. Tubiana,et al.  Acute hepatitis C in HIV‐infected men who have sex with men , 2004, HIV medicine.

[108]  E. Sagnelli,et al.  Influence of Chronic Coinfection with Hepatitis B and C Virus on Liver Histology , 2004, Infection.

[109]  H. Saito,et al.  Efficacy of non-invasive elastometry on staging of hepatic fibrosis. , 2004, Hepatology research : the official journal of the Japan Society of Hepatology.

[110]  E. Schiff,et al.  Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. , 2004, Gastroenterology.

[111]  B. Gazzard,et al.  Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study , 2004, The Lancet.

[112]  William M. Lee,et al.  Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. , 2004, Gastroenterology.

[113]  C. Giffen,et al.  Treatment of chronic hepatitis C in HIV/HCV‐coinfection with interferon α‐2b+ full‐course vs. 16‐week delayed ribavirin , 2004, Hepatology.

[114]  I. Suh,et al.  Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study , 2004, BMJ : British Medical Journal.

[115]  P. Marcellin,et al.  Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. , 2004, Annals of internal medicine.

[116]  P. Marcellin,et al.  Effect of peginterferon alfa‐2a on liver histology in chronic hepatitis C: A meta‐analysis of individual patient data , 2004, Hepatology.

[117]  V. Soriano,et al.  Care of patients with hepatitis C and HIV co-infection. , 2004, AIDS.

[118]  A. Muriel,et al.  High Rate of Didanosine-Related Mitochondrial Toxicity in HIV/HCV-Coinfected Patients Receiving Ribavirin , 2004, Antiviral therapy.

[119]  V. Paradis,et al.  Sampling variability of liver fibrosis in chronic hepatitis C , 2003, Hepatology.

[120]  G. Lüchters,et al.  Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection , 2003, The Lancet.

[121]  A. Perelson,et al.  Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection. , 2003, The Journal of infectious diseases.

[122]  N. Heaton,et al.  Survival of human immunodeficiency virus-infected liver transplant recipients. , 2003, The Journal of infectious diseases.

[123]  Richard D Moore,et al.  Hospitalization Rates Differ by Hepatitis C Status in an Urban HIV Cohort , 2003, Journal of acquired immune deficiency syndromes.

[124]  P. Morlat,et al.  Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study) , 2003, AIDS.

[125]  N. Gruener,et al.  Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. , 2003, Gastroenterology.

[126]  V. Soriano,et al.  Pegylated IFN-α2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients , 2003 .

[127]  V. Soriano,et al.  Hepatitis C Virus-Rna Clearance in HIV-Coinfected Patients with Chronic Hepatitis C Treated with Pegylated Interferon plus Ribavirin , 2003, Antiviral therapy.

[128]  M. Buti,et al.  Extending combination therapy with peginterferon alfa‐2b plus ribavirin for genotype 1 chronic hepatitis C late responders: A report of 9 cases , 2003, Hepatology.

[129]  C. Puoti.  HCV carriers with persistently normal aminotransferase levels: normal does not always mean healthy. , 2003, Journal of hepatology.

[130]  C. Katlama,et al.  Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients , 2003, AIDS.

[131]  V. Soriano,et al.  Treatment of chronic hepatitis C virus infection: we must target the virus or liver fibrosis? , 2003, AIDS.

[132]  Y. Jeng,et al.  Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients , 2003, Hepatology.

[133]  G. Sirera,et al.  Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co‐infected patients , 2003, Journal of viral hepatitis.

[134]  V. Soriano,et al.  Incidence of Liver Injury After Beginning Antiretroviral Therapy with Efavirenz or Nevirapine , 2003, HIV clinical trials.

[135]  R. Roldán,et al.  Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[136]  T. Poynard,et al.  Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy , 2003, AIDS.

[137]  B. Clotet,et al.  Early HCV dynamics on Peg-interferon and ribavirin in HIV/HCV co-infection: indications for the investigation of new treatment approaches , 2003, AIDS.

[138]  C. Quereda,et al.  Pegylated interferon α2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients , 2003, AIDS.

[139]  M. S. Wilson,et al.  The Clinical Spectrum of Hepatitis C Virus in HIV Coinfection , 2003, Journal of acquired immune deficiency syndromes.

[140]  M. Kazatchkine,et al.  Severe liver mitochondriopathy with normal liver histology and normal lactate levels in patients receiving nucleoside analogues. , 2002, AIDS.

[141]  V. Soriano,et al.  Weight loss in HIV-infected patients. , 2002, The New England journal of medicine.

[142]  William M. Lee,et al.  Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. , 2002, Gastroenterology.

[143]  Llorenç Quintó,et al.  Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model , 2002, Hepatology.

[144]  E. Schiff,et al.  Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection , 2002, American Journal of Gastroenterology.

[145]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[146]  A. Alberti,et al.  Prevalence of Liver Disease in a Population of Asymptomatic Persons with Hepatitis C Virus Infection , 2002, Annals of Internal Medicine.

[147]  Richard D Moore,et al.  Hepatitis C and progression of HIV disease. , 2002, JAMA.

[148]  A. Zanella,et al.  Updated Definitions of Healthy Ranges for Serum Alanine Aminotransferase Levels , 2002, Annals of Internal Medicine.

[149]  M. Puoti,et al.  Histological and virological features and follow-up of hepatitis C virus carriers with normal aminotransferase levels: the Italian prospective study of the asymptomatic C carriers (ISACC). , 2002, Journal of hepatology.

[150]  V. Soriano,et al.  Role of Hepatitis C Virus Genotype in the Development of Severe Transaminase Elevation After the Introduction of Antiretroviral Therapy , 2002, Journal of acquired immune deficiency syndromes.

[151]  V. Soriano,et al.  Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. , 2002, AIDS.

[152]  V. Soriano,et al.  Liver toxicity caused by nevirapine. , 2002, AIDS.

[153]  R. Chaisson,et al.  Hepatotoxicity associated with nevirapine or efavirenz‐containing antiretroviral therapy: Role of hepatitis C and B infections , 2002, Hepatology.

[154]  A. Aceti,et al.  Hepatotoxicity Development During Antiretroviral Therapy Containing Protease Inhibitors in Patients With HIV: The Role of Hepatitis B and C Virus Infection , 2002, Journal of acquired immune deficiency syndromes.

[155]  C. Trautwein,et al.  Treatment of acute hepatitis C with interferon alfa-2b. , 2001, The New England journal of medicine.

[156]  J. González-lahoz,et al.  Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. , 2001, AIDS research and human retroviruses.

[157]  P. Marcellin,et al.  Prospective study on anti‐hepatitis C virus–positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA , 2001, Hepatology.

[158]  M. Buti,et al.  Role of hepatitis B, C, and D viruses in dual and triple infection: Influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference , 2001, Hepatology.

[159]  Andrew Phillips,et al.  Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy , 2001, AIDS.

[160]  D. Snydman,et al.  Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[161]  A. Lafeuillade,et al.  Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection , 2001, The Lancet.

[162]  P. Reiss,et al.  Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection , 2000, AIDS.

[163]  M. Dubé.  Disorders of glucose metabolism in patients infected with human immunodeficiency virus. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[164]  J. Wong,et al.  Watchful Waiting with Periodic Liver Biopsy versus Immediate Empirical Therapy for Histologically Mild Chronic Hepatitis C: A Cost-Effectiveness Analysis , 2000, Annals of Internal Medicine.

[165]  G. Hajian,et al.  Population Pharmacokinetic and Pharmacodynamic Analysis of Ribavirin in Patients With Chronic Hepatitis C , 2000, Therapeutic drug monitoring.

[166]  F. Montagnese,et al.  Hepatitis C virus carriers with persistently normal aminotransferase levels: healthy people or true patients? , 2000, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[167]  F. Degos,et al.  Practices of Liver Biopsy in France: Results of a Prospective Nationwide Survey , 2000, Hepatology.

[168]  M. Kazatchkine,et al.  Lack of interference between ribavirin and nucleosidic analogues in HIV/HCV co-infected individuals undergoing concomitant antiretroviral and anti-HCV combination therapy. , 2000, AIDS.

[169]  D. Vlahov,et al.  The natural history of hepatitis C virus infection: host, viral, and environmental factors. , 2000, JAMA.

[170]  R. Torella,et al.  Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. , 2000, Gastroenterology.

[171]  R. Chaisson,et al.  Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. , 2000, JAMA.

[172]  C. Garret,et al.  A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. , 1999, Gastroenterology.

[173]  C. Katlama,et al.  Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients , 1999, Hepatology.

[174]  M. Velasco,et al.  Resolution of chronic hepatitis B after ritonavir treatment in an HIV-infected patient. , 1999, The New England journal of medicine.

[175]  C. Hart,et al.  Effect of ribavirin on zidovudine efficacy and toxicity in vitro: a concentration-dependent interaction. , 1998, AIDS research and human retroviruses.

[176]  V. Soriano,et al.  Hepatotoxicity after introduction of highly active antiretroviral therapy. , 1998, AIDS.

[177]  S. Rossi,et al.  Treatment of chronic hepatitis D with interferon alpha-2b in patients with human immunodeficiency virus infection. , 1998, Journal of hepatology.

[178]  M. Vidaud,et al.  Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity , 1998, Hepatology.

[179]  Lenzo Np,et al.  Hepatic steatosis and lactic acidosis associated with stavudine treatment in an HIV patient: a case report. , 1997 .

[180]  J. Ludwig,et al.  The long‐term pathological evolution of chronic hepatitis C , 1996, Hepatology.

[181]  H. Conjeevaram,et al.  Volunteer Blood Donors with Antibody to Hepatitis C Virus: Clinical, Biochemical, Virologic, and Histologic Features , 1995, Annals of Internal Medicine.

[182]  M. Shindo,et al.  The virological and histological states of anti‐hepatitis C virus–positive subjects with normal liver biochemical values , 1995, Hepatology.

[183]  J. González-lahoz,et al.  More severe course of delta hepatitis in HIV-infected patients [L] , 1995, Genitourinary medicine.

[184]  M. Mondelli,et al.  Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities , 1995, Hepatology.

[185]  R. Robinson.  Economic Evaluation and Health Care Cost-effectiveness analysis , 2006 .

[186]  J. Rodríguez-Orengo,et al.  Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. , 2006, Journal of hepatology.

[187]  C. B. Hare,et al.  Clinical presentation and course of acute hepatitis C infection in HIV-infected patients. , 2006, Journal of acquired immune deficiency syndromes.

[188]  Marina Núñez,et al.  Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. , 2006, Journal of hepatology.

[189]  V. Soriano.  Treatment of chronic hepatitis C in HIV-positive individuals: selection of candidates. , 2006, Journal of hepatology.

[190]  M. Buti,et al.  Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. , 2006, Journal of hepatology.

[191]  A. Andriulli,et al.  P.324 Pegylated interferon alpha-2b monotherapy and in combination with ribavirin in chronic hepatitis delta , 2006 .

[192]  M. Alter,et al.  Epidemiology of viral hepatitis and HIV co-infection. , 2006, Journal of hepatology.

[193]  J. Miro,et al.  Management of end stage liver disease (ESLD): what is the current role of orthotopic liver transplantation (OLT)? , 2006, Journal of hepatology.

[194]  J. Gerber,et al.  Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[195]  J. J. de la Cruz,et al.  Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[196]  C. Katlama,et al.  Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. , 2002, AIDS.

[197]  F. Callea,et al.  Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus. , 2001, The Journal of infectious diseases.

[198]  E. Zafrani,et al.  Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. , 1999, Journal of hepatology.

[199]  N. Lenzo,et al.  Hepatic steatosis and lactic acidosis associated with stavudine treatment in an HIV patient: a case report. , 1997, AIDS.

[200]  M. Colombo,et al.  Influence of different hepatitis C virus genotypes on the course of asymptomatic hepatitis C virus infection. , 1996, Gastroenterology.